At Innovative Care, we want to keep you informed about an important change regarding compounded semaglutide following the FDA’s recent announcement. If you are currently using compounded GLP-1 medication, here’s what you need to know and how we can help ensure continuity of your care.
On February 21, 2024, the FDA announced the end of the shortage of Ozempic® and Wegovy®. As a result, compounding pharmacies will no longer be authorized to produce compounded semaglutide after mid-April (60 days from the FDA’s decision).
This means that while we can continue prescribing compounded semaglutide in the short term, we will no longer be able to offer it after mid-April.
We understand that this change may be unexpected, but rest assured, there are alternative options available.
Eli Lilly has recently announced a price reduction for self-pay vials of Zepbound (tirzepatide) and an expansion of their savings program.
An appointment with your provider is required for refills of either medication. You may use insurance for this visit, or self-pay $100.
✔️ You can continue receiving compounded semaglutide until April 20 (tentative date).
✔️ After that date, you will need to switch to either:
If you don’t have a follow-up appointment scheduled in the next month, we strongly encourage you to book one now to discuss your transition plan.
We are here to ensure a smooth transition and help you find the best treatment option for your health goals. If you have questions or need guidance on switching medications, schedule an appointment as soon as possible.